drugset
drugset / Trial / NCT03679650

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

NCT03679650 ↗

Phase 1 Active not recruiting 28 enrolled Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute · collabNational Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: * Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) * Decitabine, a chemotherapy drug

Timeline

Start
2018-10-11
Primary completion
2026-03-31
Completion
2026-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject DC/AML fusion cells Vaccine — —

Indications

acute myeloid leukemia